Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
14 August 2018Website:
http://www.aridispharma.comNext earnings report:
09 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ARDS Latest News
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments.
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS).
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
What type of business is Aridis Pharmaceuticals?
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
What sector is Aridis Pharmaceuticals in?
Aridis Pharmaceuticals is in the Healthcare sector
What industry is Aridis Pharmaceuticals in?
Aridis Pharmaceuticals is in the Biotechnology industry
What country is Aridis Pharmaceuticals from?
Aridis Pharmaceuticals is headquartered in United States
When did Aridis Pharmaceuticals go public?
Aridis Pharmaceuticals initial public offering (IPO) was on 14 August 2018
What is Aridis Pharmaceuticals website?
https://www.aridispharma.com
Is Aridis Pharmaceuticals in the S&P 500?
No, Aridis Pharmaceuticals is not included in the S&P 500 index
Is Aridis Pharmaceuticals in the NASDAQ 100?
No, Aridis Pharmaceuticals is not included in the NASDAQ 100 index
Is Aridis Pharmaceuticals in the Dow Jones?
No, Aridis Pharmaceuticals is not included in the Dow Jones index
When does Aridis Pharmaceuticals report earnings?
The next expected earnings date for Aridis Pharmaceuticals is 09 July 2024